



April 1, 2025

Announcement of Strengthening Management Structure at iXgene

iXgene Inc. (Headquarters: Tokyo, Japan; Representative Director: Toshiharu Furukawa; hereinafter referred to as "the Company") announces that, at the shareholders' meeting held in March 2025, it was resolved that current Director and COO, Atsushi Mizuno, will be appointed as Representative Director and COO. Consequently, the Company will transition to a dual representative structure alongside current Representative Director and CEO, Toshiharu Furukawa.

Background of Transition to Dual Representative Structure

Since its founding, the Company has been advancing its business with the aim of developing treatments for intractable diseases lacking existing therapies, utilizing genome-edited iPS cells that combine iPS cell technology with genome editing technology.

This transition to a dual representative structure aims to further accelerate the implementation of preclinical and clinical trials. By enhancing decision-making speed and strengthening the management system, the CEO and COO will leverage their respective strengths to drive both strategy and execution, thereby promoting further business growth and enhancing corporate value.

New Management Structure (Effective March 26, 2025)

- Representative Director and CEO: Toshiharu Furukawa (Incumbent)
- Representative Director and COO: Atsushi Mizuno (Newly appointed; previously Director and COO)

Under the leadership of both representatives, the Company will continue to make every effort to deliver its treatments to patients as soon as possible. We sincerely appreciate your continued support and guidance.

Company Overview



- Company Name: iXgene Inc.
- Established: January 6, 2020
- Headquarters: 1-14-1 Yotsuya, Shinjuku-ku, Tokyo, Japan
- Business Description: Development of treatments for intractable diseases using genome-edited iPS cells
- Representative Directors: Toshiharu Furukawa, Atsushi Mizuno
- Company Website: <http://www.ixgene.inc>